Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dobutamine vs isoproterenol for induction of supraventricular arrhythmias after ablation
IRCT20230918059453N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dobutamine and isoprenaline in Supraventricular arrhythmia (SVA) and arrhythmia (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Re-ablation. Started Dec 2023; status: completed.
02
Drugs
dobutamineisoprenaline
03
Conditions
Supraventricular arrhythmia (SVA)arrhythmia
Beyond the preview
Go deeper on IRCT20230918059453N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230918059453N1.